Apellis Pharmaceuticals is laying off one quarter of its workforce in an overhaul of its business designed to focus resources on a newly approved vision loss drug.
The job cuts announced Tuesday will affect about 225 employees. The company’s field-based sales staff and medical employees are minimally affected by the reorganization, which will be completed during the third quarter, Apellis said.
Apellis also plans to trim its research spending. The company will stop developing preclinical treatments for geographic atrophy and an unspecified brain disease, as well as abandon a plan to study one of its marketed medicines alongside an RNA-based treatment.
Apellis wont start any new development on a systemically administered version of peg…
Read the full article at: https://www.biopharmadive.com/news/apellis-layoffs-biotech-restructuring-syfovre/692104/